Denna webbsida är endast avsedd för läkare och sjukvårdspersonal med förskrivningsrätt.

DENNA WEBBPLATS ANVÄNDER KAKOR (COOKIES). Vi använder kakor för att kunna ge dig en bra upplevelse när du besöker vår webbplats. Kakor används för webbstatistik för att kunna göra förbättringar på webbplatsen. Läs mer om vår cookie policy. Du kan välja att godkänna att vi använder kakor under ditt besök genom att klicka på “Jag godkänner”.

AlzeCure Pharma broadcasts live event about the phase II candidate ACD440 against neuropathic pain

AlzeCure Pharma

10 okt 2024

During the symposium, titled ”ACD440 – A novel non-opioid analgesic”, Dr. Karlsten will provide an overview of the area of pain. Märta Segerdahl, CMO and project manager, will also give an update on AlzeCure’s clinical phase II candidate, ACD440, which is being developed as a new topical treatment for patients with chronic neuropathic pain. In addition, Dr. Karlsten, together with AlzeCure’s CEO Martin Jönsson and CMO Märta Segerdahl, will answer questions about the company’s progress in the development of new pain treatments.

ACD440 is a first-in-class TRPV1 antagonist in clinical phase being developed as a new topical local treatment for peripheral neuropathic pain. The drug candidate, which was incorporated via strategic in-licensing, originated in Big Pharma and is based on a strong scientific foundation, which was awarded a Nobel Prize in 2021. The substance is developed as a gel for topical use, which keeps the systemic exposure very low while the local concentration of the substance can be kept high to achieve a maximum analgesic effect, as well as over a long period of time.

In 2023, AlzeCure reported positive proof-of-mechanism results (PoM) with ACD440 in patients with chronic peripheral neuropathic pain, i.e. the drug candidate had an effect on the intended target mechanism, and a clear and significant analgesic effect was observed on pain induced by cold and heat. This pain was reduced by approximately 50%, a significant and clinically relevant reduction. Temperature hypersensitivity is very common in the skin area where the patients have their neuropathic pain, and is a major problem in everyday life for these individuals. These positive PoM results from this phase II study were in line with previously reported phase I results. Furthermore, it was observed that ACD440, given as a topical gel applied to the skin in the area of pain, was well tolerated and both the substance and the route of administration show good suitability for further clinical development.

Agenda:
13:00 – Introduction to AlzeCure and today’s agenda – Martin Jönsson, CEO AlzeCure
13:10 – Pain: background and medical needs – Rolf Karlsten, MD, PhD, Uppsala University Hospital
13:30 – ACD440: A novel non-opioid analgesic – Märta Segerdahl, MD, PhD, CMO, AlzeCure
13:45 – Q&A
14:00 – Final comments – Martin Jönsson, CEO AlzeCure


Martin Jönsson, CEO & Märta Segerdahl, MD, PhD, CMO, AlzeCure.

The event is held in English and takes place in collaboration with Finwire, does not require advance registration and can be followed via: https://www.finwire.tv/webcast/alzecure-pharma/acd440-a-novel-non-opioid-analgesic/

The presentation will also be available afterwards on AlzeCure’s website https://www.alzecurepharma.se/en/presentations-and-interviews/ and on the company’s YouTube channel: https://www.youtube.com/@alzecurepharma5138.